Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Subscribe To Our Newsletter & Stay Updated
